Genomic sequences of *Streptococcus agalactiae* with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance

Michel DOUMITH¹, Shazad MUSHTAQ¹, Veronique MARTIN²,³, Aiysha CHAUDHRY¹, Rachael ADKIN¹, Juliana COELHO¹, Vicki CHALKER¹, Alasdair MACGOWAN³, Neil WOODFORD¹, David M LIVERMORE¹,⁴* & the BSAC Standing Committee on Resistance Surveillance¹

¹National Infection Service, Public Health England, London NW9 5EQ, UK; ²British Society for Antimicrobial Chemotherapy, Birmingham, B1 3NJ, UK; Medical Microbiology, ³Southmead Hospital, Bristol, BS10 5NB, UK, ⁴Norwich Medical School, University of East Anglia NR4 7TJ, UK.

**Running head:** Highly gentamicin resistant *S. agalactiae*

* Corresponding author
¹ For members, see Acknowledgements

Norwich Medical School,
Floor 2, Bob Champion Research & Educational Building,
James Watson Road,
University of East Anglia,
Norwich Research Park,
NORWICH, NR4 7UQ
Tel: +44-(0)1603-597-568
e-mail: d.livermore@uea.ac.uk
**Background.** Like other streptococci, *Streptococcus agalactiae* typically has intrinsic low-level aminoglycoside resistance. High-level gentamicin resistance was seen in two of 1125 isolates collected in the British Society for Antimicrobial Chemotherapy (BSAC) Bacteraemia Surveillance Programme between 2001 and 2014. These organisms, both isolated in 2014, were characterised. **Methods.** Identifications were by latex agglutination, MICs by BSAC agar dilution, and sequencing by Illumina methodology. **Results.** Gentamicin MICs were $>1024$ mg/L versus a species mode of 8 mg/L; both isolates also were unusually ciprofloxacin resistant with MICs of 64 mg/L versus a species mode of 1 mg/L. They were distinct by sequence, but both belonged to the ST19 clone, which occurs globally. Both had $\text{aac6'}$-$\text{aph2''}$, carried by different transposons, explaining their gentamicin resistance, and had $\text{gyrA}[81: \text{S-L}]$;$\text{parC}[79: \text{S-Y}]$, accounting for ciprofloxacin resistance. **Conclusion.** These are the first multiresistant *S. agalactiae* with the bifunctional AAC(6')-APH(2'') enzyme to be reported in the UK for over 10 years. Despite belonging to the same clonal complex, the two isolates and their resistance transposons were distinct. Both retained full susceptibility to penicillin, but any penicillin-gentamicin synergy is likely to be lost.
**Introduction**

*Streptococcus agalactiae* (Group B streptococcus, GBS) is an important agent of neonatal sepsis. In 2010, the UK incidence was 0.41 cases /1000 live births, with a growing number of adult septicaemias also recorded. Most clinical isolates belong to clonal complexes (CCs) 1,10,17,19, 23 and, among these, CC17 is considered to have increased virulence potential. Antibiotic resistance is not a major issue in the species. Penicillin remains the treatment of choice and resistance is extremely rare, though strains with reduced susceptibility are a growing problem in Japan. Tetracycline resistance is frequent, but is of limited clinical relevance, given that tetracyclines are contra-indicated in neonates and their expectant mothers, who form the largest patient groups. Like all streptococci, GBS have low-level intrinsic resistance to gentamicin, reflecting poor uptake; high-level resistance, mediated by the bifunctional AAC(6')-APH(2") enzyme that is prevalent in enterococci and staphylococci, has been reported on a few occasions in GBS in the UK and France, with some recent proliferation in Argentina, but is considered still to be exceptional.

Between 2001 and 2014, the BSAC Bacteraemia Surveillance Programme examined 1125 *S. agalactiae* from over 70 UK and Irish sites. In 2014, for the first time, we identified two isolates of this species with high-level gentamicin resistance. They were referred from separate hospitals, and both also were unusually resistant to ciprofloxacin. These genomes of these organisms were sequenced to elucidate their relatedness and the genetic bases of their resistance phenotypes.

**Materials and methods**

*Isolates and susceptibility testing*

The collection strategy for the BSAC Bacteraemia Surveillance Programme has been described. Until 2008, 25 UK and Irish diagnostic laboratories contributed up to 10 consecutive β-haemolytic streptococci per annum; subsequently the number of laboratories was increased to 40 and the number of isolates per site reduced to seven. There is some turnover of collection laboratories, and 70 sites have participated during the period
reviewed (2001-14). On receipt by PHE, β-haemolytic streptococci are identified using the Streptococcal Grouping Latex kit (Pro-Lab Diagnostics, Bromborough, UK) and MICs are determined by BSAC agar dilution. The two highly-gentamicin-resistant isolates were collected in 2014 at separate hospitals 70 miles (112 km) apart: BSB14107 was from a 28-year-old woman and was isolated in the January; BSB14238 was from a 33-year-old man and was isolated in the April. We do not have clinical details for the patients.

**Sequencing**

Isolates were sequenced at PHE’s Genomic Service Delivery Unit on an Illumina HiSeq 2500 platform using the Nextera XT sample preparation method. In-silico MLST was performed using the mapping-based tool MOST, with reference sequences downloaded from the *S. agalactiae* MLST database. Antimicrobial resistance genes were detected using a locally-curated database of resistance determinants and the in-house algorithm ‘GeneFinder’. Short reads were assembled into contigs using SPAdes and those carrying the gentamicin resistance determinant were identified by BLAST. Coding sequences were determined with Glimmer with functions inferred from homology searches with BLAST. The genetic relatedness of the isolates was assessed by Single Nucleotide Polymorphisms (SNP) analysis, as previously described.

**Results and Discussion**

**Susceptibility**

Among 3218 β-haemolytic streptococci collected from bacteraemic patients by the BSAC Surveillance Programme from 2001-2014, 1125 were identified as *S. agalactiae*. MIC distributions for these are shown in Table 1. Isolates BSB14107 and BSB14238 were the only two with high-level resistance to gentamicin and were among a small minority (7/1125) with high-level ciprofloxacin resistance. Both also were highly resistant to tetracycline, though this trait was highly prevalent in the whole collection, with MICs ≥16 mg/L for 77.5%
of the isolates. Both retained normal susceptibility to \( \beta \)-lactams and vancomycin (Table 1).

BSB14107 was highly resistant to both erythromycin and clindamycin (MICs >128 mg/L); BSB14238 had low-level resistance to erythromycin (MIC 2 mg/L), but remained fully susceptible to clindamycin (MIC 0.12 mg/L).

Sequencing and strain characterisation

Based on in-silico MLST, using whole genome sequences, both resistant isolates belonged to the ST19 clone, which occurs internationally. Nevertheless, their sequences differed by at least 934 SNPs, indicating them to be distinct. The phenotypes of both isolates (Table 1) could be explained by the acquired resistance genes or mutations identified. Both carried \( \text{aac}(6')\text{-aph}(2'') \), explaining high-level gentamicin resistance; both also had chromosomal \( \text{gyrA}[81:S-L];\text{parC}[79:S-Y] \) mutations, explaining high-level ciprofloxacin resistance.

Furthermore, both had \( \text{tet}(M) \), accounting for tetracycline resistance; this was embedded in the same position in Tn916-like elements in both strains and was unlinked to \( \text{aac}(6')\text{-aph}(2'') \). BSB14107 additionally had \( \text{mef}(E), \text{erm}(B), \text{msr}(D), \text{Isa}(E) \) and \( \text{Inu}(B) \), all of which contributed to high-level macrolide and lincosamide resistance, as observed in this strain. BSB14238 had \( \text{erm}(TR) \), explaining low-level macrolide resistance; it also carried \( \text{Inu}(C) \), but this gene does not reliably cause clindamycin resistance in streptococci\(^{15}\) and so is not discordant with observed susceptibility.

The \( \text{aac}(6')\text{-aph}(2'') \) gene was transposon-borne in both isolates, but the genetic environments (Figure 1) differed between the two organisms. In BSB14107 the arrangement most closely resembled that previously described from \textit{S. agalactiae} SGB76\(^{16}\) though this strain did not carry \( \text{aac}(6')\text{-aph}(2'') \). Specifically, \( \text{aac}(6')\text{-aph}(2'') \) was located on the same contig as a known mobile element carrying \( \text{aadE} \) and \( \text{Inu}(B) \) along with the spectinomycin adenylyltransferase determinant, \( \text{spc} \); however, no direct association with known mobile elements was apparent for \( \text{aac}(6')\text{-aph}2'' \) itself (figure 1a). In BSB14238, \( \text{aac}(6')\text{-aph}(2'') \) was linked to the insertion element IS256, as previously described in (i) Tn3706 from \textit{S. agalactiae} isolated in France in 1987\(^{17}\) and (ii) Tn4001 from...
However, only the upstream copy of IS256 was confirmed; downstream of aac(6')-aph(2") we found only the end of the putative second IS256 copy; failure to detect the entire element probably reflects problems inherent in resolving repeats in short-read assemblies.

In summary, *S. agalactiae* with high-level gentamicin resistance mediated by the bifunctional AAC(6')-APH(2") enzyme have (re-)emerged in the UK. It is unknown whether the isolates were imported or if they acquired their resistance transposons locally. Isolates with this mechanism were reported in the country in 2002, but have not, to our knowledge, been recorded subsequently. Despite belonging to ST19 and sharing exceptional fluoroquinolone resistance, the present isolates and their resistance transposons were distinct from each other: that in BSB14107 was distinct from any previously found in GBS.

Despite the organisms’ multiresistance, and their evident ability to cause infection in the source patients, their wider clinical significance is uncertain. UK guidelines advocate empirical penicillin plus gentamicin for neonatal sepsis, and similar regimens are widely used international. The general view in the UK is that the penicillin covers against GBS whilst the gentamicin covers against Enterobacteriaceae, which are the other likely pathogens in the setting. If this view is correct, high-level gentamicin resistance GBS will be of little significance. A counter view is that gentamicin may potentiate penicillins in *S. agalactiae* bacteraemia, as in streptococcal endocarditis. In this case high-level resistance would be predicated to abrogate this synergy, potentially impacting upon outcomes. There is, however, scant clinical evidence to support this latter view and a recent in vitro analysis found that gentamicin only gave a small acceleration of penicillin-mediated killing, without convincing synergy. A separate and less debatable risk is that GBS may become a vector of transposons encoding AAC(6')-APH(2"), facilitating its widening dissemination.

**Acknowledgements**

We are grateful to all the laboratories that have contributed isolates to the BSAC surveillance programme, to Profs. Paul Heath, Alan Johnson, Mike Sharland and Dr
Theresa Lamagni for helpful discussions on the clinical significance of resistant GBS and to Roger Daniel and Chenchal Dhami of PHE for their work in extracting DNA for sequencing. Current members of the BSAC Resistance Surveillance Standing Committee are Drs M Allen, DFG Brown, C. Longshaw and Profs DM Livermore and AP MacGowan.

Funding

The BSAC surveillance programme has been funded by many pharmaceutical companies during the 14 years reviewed here. A full listing is available in [http://www.bsacsurv.org/about/sponsors-2/](http://www.bsacsurv.org/about/sponsors-2/). Additional characterisation and sequencing of the isolates was funded internally by PHE.

Transparency declarations

**DML:** Advisory Boards or ad-hoc consultancy Accelerate, Achaogen, Adenium, Allocra, AstraZeneca, Auspherix, Basilea, BioVersys, Cubist, Centauri, Discuva, Meiji, Pfizer, Roche, Shionogi, Tetrance, VenatoRx, Wockhardt, Zambon, Zealand. Paid lectures – AstraZeneca, Beckman-Coulter, Cepheid, Merck Nordic and Wockhardt. Relevant shareholdings– Dechra, GSK, Merck, Perkin Elmer, Pfizer amounting to <10% of portfolio value. **APMcG:** Speakers’ bureau for Astellas, Grant investigator for Cubist/Merck, The Medicine Company, Bayer Healthcare, Achaogen and Tetrance. **All others:** No personal interests, however, PHE’s AMRHAI Reference Unit has received financial support for conference attendance, lectures, research projects or contracted evaluations from numerous sources, including: Accelerate Diagnostics, Achaogen Inc, Allocra Therapeutics, Amplex, AstraZeneca UK Ltd, Basilea Pharmaceutica, Becton Dickinson Diagnostics, bioMérieux, Bio-Rad Laboratories, The BSAC, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, Food Standards Agency, GlaxoSmithKline Services Ltd, Henry Stewart Talks, IHMA Ltd., Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe & Dohme Corp., Meiji Seika Pharmo Co., Ltd, Mobidiag, Momentum Biosciences Ltd, Nordic Pharma Ltd, Norgine Pharmaceuticals,
References


2. Da Cunha V, Davies MR, Douarre PE et al. Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline. Nat Commun 2014; 5: 4544.


10. S. agalactiae MLST database https://pubmlst.org/sagalactiae


